In Brief: Immunex Novantrone
Immunex Novantrone: Firm files supplemental NDA for use of mitoxantrone in the treatment of hormone-refractory prostate cancer, Immunex announces May 14. The company is seeking a priority review for the NDA, which includes two Phase III trials in 303 patients who previously had failed hormone treatment. In one study, serum PSA declined by 50% or more for 44% of the patients receiving Novantrone plus prednisone compared to 33% of the patients on prednisone alone. In the second study, PSA decreases of 50% or more were seen in 31% of the Novantrone patients compared to 17% of the steroid-only group. In addition, Novantrone treatment resulted in significant improvements in pain and overall quality of life. Novantrone is marketed in the U.S. as first-line therapy for acute myelogenous leukemia...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth